Celcuity Inc. (NASDAQ:CELC) Given Consensus Recommendation of “Buy” by Analysts

Celcuity Inc. (NASDAQ:CELC) has earned an average recommendation of “Buy” from the seven ratings firms that are presently covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $30.17.

CELC has been the topic of a number of recent research reports. HC Wainwright reissued a “buy” rating and issued a $27.00 target price on shares of Celcuity in a research note on Friday, November 15th. Needham & Company LLC increased their price objective on shares of Celcuity from $23.00 to $29.00 and gave the company a “buy” rating in a research report on Thursday, February 6th.

Celcuity Stock Up 11.7 %

Shares of Celcuity stock opened at $9.94 on Wednesday. Celcuity has a 1 year low of $8.53 and a 1 year high of $22.19. The firm has a market cap of $369.07 million, a price-to-earnings ratio of -3.81 and a beta of 0.73. The company has a 50-day moving average of $11.99 and a 200 day moving average of $13.74. The company has a debt-to-equity ratio of 0.65, a current ratio of 10.35 and a quick ratio of 10.36.

Institutional Investors Weigh In On Celcuity

Several institutional investors have recently modified their holdings of the business. Prospera Private Wealth LLC purchased a new position in Celcuity in the 3rd quarter worth about $35,000. Summit Investment Advisors Inc. raised its holdings in shares of Celcuity by 49.5% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,421 shares of the company’s stock valued at $45,000 after purchasing an additional 1,132 shares during the last quarter. Aquatic Capital Management LLC bought a new position in Celcuity during the fourth quarter valued at approximately $50,000. The Manufacturers Life Insurance Company purchased a new stake in Celcuity in the fourth quarter worth approximately $142,000. Finally, Bleakley Financial Group LLC bought a new stake in Celcuity in the 4th quarter worth approximately $146,000. 63.33% of the stock is owned by hedge funds and other institutional investors.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.